FTC Declines To Challenge Reverse Payment Deal
The Federal Trade Commission has disclosed that it will not challenge a so-called reverse payment agreement between generic-drug makers Mylan Inc., Dr. Reddy's Laboratories Inc. and Cobalt Pharmaceuticals Inc. on one...To view the full article, register now.
Already a subscriber? Click here to view full article